CStone’s CS2009 Delivers Strong NSCLC and CRC Results at ASCO 2026
SUZHOU, China, June 1, 2026 CStone Pharmaceuticals announced updated clinical data for CS2009, its investigational PD-1/VEGF/CTLA-4 trispecific antibody, at...
artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Eli Lilly FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology NSCLC Oncology oncology innovation Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory compliance targeted therapy
SUZHOU, China, June 1, 2026 CStone Pharmaceuticals announced updated clinical data for CS2009, its investigational PD-1/VEGF/CTLA-4 trispecific antibody, at...
